Cochlear (COHN) Q4 2026 Earnings Report

The call outlined clear strategic progress: a highly successful Nexa product launch, meaningful unit growth, strong services expansion in developed markets, disciplined cash and cost management, and continued heavy R&D investment into attractive pipeline programs (TICI, drug-eluting electrodes). However, material near-term challenges remain — a 3ppt gross margin decline to 71%, an underlying net profit margin below target (14% vs 18% medium-term goal), Western Europe weakness, China pricing headwinds, non-cash write-downs and FY'27 FX headwinds. Management has responded with cost optimization, targeted growth re-investment (DTC and professional referral pilots) and a conservative FY'27 outlook (low single-digit revenue growth; underlying NP $330m–$350m). Overall the call balanced tangible product and pipeline upside with notable geopolitical, reimbursement and margin pressures.

Guidance highlights: FY26 sales were $2.3bn (up 2% constant currency) with underlying net profit $322m (14% margin); Cochlear enabled >55,000 people to hear and >50,000 of its >800,000 recipients received a new speech processor. For FY27 management expects low single‑digit constant‑currency revenue growth and underlying net profit of $330–350m, with gross margin guided flat at 70–71% (assumes USD $0.70 / EUR $0.61; net‑profit sensitivity ~2% per $0.01 FX and FX net impact on FY27 profit ~‑10% after hedges; current hedging could deliver ~$25–30m). Key financial items: R&D rose 15% to $323m (14% of sales) and will be maintained at ≥12% of revenue; comparable OpEx down 1% (reported OpEx +5% including $32m restructuring and $37m STI provisioning); CapEx around $100m (FY26 ~$91m); cloud program ~$60m after tax in FY27 (total program just over $200m post‑tax); fixed costs cut by 2ppt of revenue (≈$40m run‑rate), $25m reallocated to growth, inventory reduced $75m (13% H2), working capital $789m and operating cash flow +$130m with free cash flow more than doubled. Operational guidance/assumptions include CI systems volumes +5% in FY26 (CI revenue flat; developed‑market CI revenue +1%), Nexa accounting for >95% of developed‑market implants by June with ~3% average price uplift, services +6% (developed +13%) and acoustics +1%, with services expected slightly lower in FY27 and Osia‑3 driving future acoustics growth; medium‑term target remains an 18% net‑profit margin.